A protein which binds to osteoclastogenesis inhibitory factor (OCIF)

• Main Authors: TSUDA, EISUKE, KINOSAKI, MASAHIKO, YANO, KAZUKI, GOTO, MASAAKI, YASUDA, HISATAKA, KOBAYASHI, FUMIE, WASHIDA, NAOHIRO, TAKAHASHI, KEN, NAKAGAWA, NOBUAKI, SHIMA, NOBUYUKI, TOMOYASU, AKIHIRO, YAMAGUCHI, KYOJI, MORINAGA, TOMONORI, HIGASHIO KANJI
• Format: Patent
• Language: English
• Published: 28.07.2000
• Edition: 7
• Subjects: BEER; BIOCHEMISTRY; CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOIDCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PERFORMING OPERATIONS; PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; THEIR RELEVANT APPARATUS; TRANSPORTING; VINEGAR; WINE

The protein OBM (OCIF-binding molecule) binds to osteoclastogenesis inhibitory factor (OCIF) and exhibits high affinity to OCIF. This protein has a molecular weight of 30,000-40,000 Da and an apparent weight of 90,000-110,000 when crossed linked to a monomer type OCIF. The protein exhibits activity supporting or promoting osteoclast differentiation and maturation in a co-culture system of the osteoblastic stromal cells and spleen cells in the presence bone resorption stimulating factors. A pharmaceutical composition for the treatment of bone metabolism disorders is also described.